Discovery and evaluation of novel biomarkers reveal dasatinib as a potential treatment for a specific subtype of Triple-Negative Breast Cancer
D. Ortega-Alvarez, D. Tebar-Garcia, M. Casado-Pelaez, E. Castillo-Agea, J. Balibrea-Rull, D. Olivares-Osuna, D. Perez-Parra, C. Guardia, E. Musulen, E. Vinuesa-Pitarch, E. Sanchez-Lopez, F. Postigo-Corrales, E. Ballana, A. Martinez-Cardus, M. Margeli, , V. Rodilla
This study identifies BC-markers in TNBC, links them to poor prognosis and dasatinib sensitivity, suggesting TAGLN as a predictive biomarker for targeted therapy.
bioRxiv · Jul 24, 2024 · PreprintCancer Biology